- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06819150
Effect of Bathing on Physiological Parameters, Skin, Bilirubin and Comfort Levels in Infants Receiving Phototherapy
Study Overview
Detailed Description
Neonatal jaundice (hyperbilirubinemia) causes a yellowish discolouration of the sclera and skin due to increased levels of bilirubin in the blood. Jaundice develops in 60% of term babies and 80% of premature babies in the first week of life. Currently, the appropriate treatment option for neonatal jaundice is phototherapy. Phototherapy treatment reduces bilirubin concentrations through various photochemical reactions that allow bilirubin to be excreted more easily. However, phototherapy treatment is associated with short-term side effects including transient skin rashes, diarrhoea, hyperthermia and dehydration.
Physiological reasons such as the weak connection between the epidermis and dermis layer in the skin of the newborn, the pH value of the skin being close to neutral or alkaline, and the low melanosome production increase the susceptibility of the newborn to infection and skin damage. Invasive interventions, use of antiseptics, phototherapy and various instruments may disrupt the skin integrity of the newborn. Therefore, all newborns receiving treatment and care in the neonatal intensive care unit are at risk in terms of skin integrity.
In the majority of newborn infants; jaundice develops, which can affect the newborn neurologically, motor and hearing if left untreated,. Phototherapy devices are widely used today for the treatment of jaundice. Phototherapy devices used in the treatment of jaundice have side effects such as skin rashes, diarrhea, dehydration and hyperthermia. In the literature reviewed, results were found that bathing the newborn reduces phototherapy rashes, lowers the bilirubin level and increases the comfort of the newborn. Also in the literature; There are studies showing that one of the most suitable bathing methods for a newborn is bathtub bathing and that bathing with baby shampoo is not harmful to the newborn.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Perihan B Çalışkan, MSc student
- Phone Number: +90 5061626224 +90 5061626224
- Email: perihanbeyza99@gmail.com
Study Contact Backup
- Name: Raziye Çelen, Asst. Prof.
- Phone Number: +90 0332 241 01 10
- Email: rturgut42@gmail.com
Study Locations
-
-
Merkez
-
Kütahya, Merkez, Turkey, 43050
- Recruiting
- Kütahya Şehir Hospital
-
Contact:
- Raziye Çelen, Asst. Prof.
- Phone Number: +90 0332 241 01 10
- Email: rturgut42@gmail.com
-
Contact:
- Perihan B Çalışkan, MSc student
- Phone Number: +90 5061626224 +90 506 162 6224
- Email: perihanbeyza99@gmail.com
-
Principal Investigator:
- Perihan B Çalışkan, MSc student
-
Sub-Investigator:
- Raziye Çelen, Asst. Prof.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Born at 35-41 gestational weeks
- Indirect hyperbilirubinaemia diagnosed at 24 hours of birth or more,
- No health problems,
- Indication for phototherapy treatment
- Stable vital signs
- Whose parents agreed to participate in the study
Exclusion Criteria:
- Newborns with ABO and Rh incompatibility,
- Direct diagnosis of hyperbilirubinaemia,
- Congenital anomaly,
- With skin lesions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Newborn bathing
The term and preterm infants in the experimental group will have a bathtub bath before starting phototherapy treatment.
|
The babies in the experimental group will have a bathtub bath before starting phototherapy treatment.
|
|
No Intervention: Standard of care
No intervention other than routine clinical practices will be applied to the control group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Infant Information Form
Time Frame: First measurement-First day of hospitalization
|
The form, prepared by the researchers based on the literature, includes questions containing natal-postnatal information of preterm and term infants (date of birth, gestational week, postnatal age, gender, birth weight, mode of delivery, NICU admission date, initiation time of phototherapy, etc.).
|
First measurement-First day of hospitalization
|
|
Follow-up form for physiologic parameters - Heart rate
Time Frame: Heart rate will be measured 10 minutes before the intervention (T0), 30 minutes (T1), 60 minutes (T2) and 6 hours (T3) after the intervention.
|
Heart rate will be measured 10 minutes before the intervention, 30 minutes, 60 minutes and 6 hours after the intervention.
|
Heart rate will be measured 10 minutes before the intervention (T0), 30 minutes (T1), 60 minutes (T2) and 6 hours (T3) after the intervention.
|
|
Follow-up form for physiologic parameters -Respiratory rate
Time Frame: Respiratory rate will be measured 10 minutes before the intervention (T0), 30 minutes (T1), 60 minutes (T2) and 6 hours (T3) after the intervention.
|
Respiratory rate will be measured 10 minutes before the intervention, 30 minutes, 60 minutes and 6 hours after the intervention.
|
Respiratory rate will be measured 10 minutes before the intervention (T0), 30 minutes (T1), 60 minutes (T2) and 6 hours (T3) after the intervention.
|
|
Follow-up form for physiologic parameters- Body temperature
Time Frame: Body temperature will be measured 10 minutes before the intervention (T0), 30 minutes (T1), 60 minutes (T2) and 6 hours (T3) after the intervention.
|
Body temperature will be measured 10 minutes before the intervention, 30 minutes, 60 minutes and 6 hours after the intervention.
|
Body temperature will be measured 10 minutes before the intervention (T0), 30 minutes (T1), 60 minutes (T2) and 6 hours (T3) after the intervention.
|
|
Follow-up form for physiologic parameters- Oxygen saturation
Time Frame: Oxygen saturation will be measured 10 minutes before the intervention (T0), 30 minutes (T1), 60 minutes (T2) and 6 hours (T3) after the intervention.
|
Oxygen saturation will be measured 10 minutes before the intervention, 30 minutes, 60 minutes and 6 hours after the intervention.
|
Oxygen saturation will be measured 10 minutes before the intervention (T0), 30 minutes (T1), 60 minutes (T2) and 6 hours (T3) after the intervention.
|
|
Follow-up form for Skin moisture
Time Frame: Skin moisture will be measured 10 minutes before the intervention (T0), 30 minutes (T1), 60 minutes (T2) and 6 hours (T3) after the intervention.
|
Skin moisture will be measured using a device (Digital Moisture Monitor for Skin) on the forehead, abdomen, back, arms (right-left) and legs (right-left).
|
Skin moisture will be measured 10 minutes before the intervention (T0), 30 minutes (T1), 60 minutes (T2) and 6 hours (T3) after the intervention.
|
|
Neonatal Skin Condition Score
Time Frame: Neonatal Skin Condition Assessment Scale, will assess the infants' skin condition 10 minutes before treatment/bath (T0) The infants' skin condition will then be reassessed 30 minutes (T1), 60 minutes (T2) and 6 hours (T3) after bath or treatment.
|
Neonatal Skin Condition Assessment Scale, will assess the infants' skin condition 10 minutes before treatment/bath (T0) The infants' skin condition will then be reassessed 30 minutes (T1), 60 minutes (T2) and 6 hours (T3) after bath or treatment.
|
Neonatal Skin Condition Assessment Scale, will assess the infants' skin condition 10 minutes before treatment/bath (T0) The infants' skin condition will then be reassessed 30 minutes (T1), 60 minutes (T2) and 6 hours (T3) after bath or treatment.
|
|
Bilirubin level
Time Frame: In the experimental and control groups, the total serum bilirubin levels will be evaluated 10 minutes before treatment/bathing (T0). The bilirubin levels will be measured for the second time at 24 hours after the start of phototherapy treatment (T1).
|
In the experimental and control groups, the total serum bilirubin levels will be evaluated 10 minutes before treatment/bathing (T0).
The bilirubin levels will be measured for the second time at 24 hours after the start of phototherapy treatment (T1).
|
In the experimental and control groups, the total serum bilirubin levels will be evaluated 10 minutes before treatment/bathing (T0). The bilirubin levels will be measured for the second time at 24 hours after the start of phototherapy treatment (T1).
|
|
The comfort level
Time Frame: The comfort level of the babies in the experimental and control groups will be evaluated 10 minutes before the treatment/bath. The comfort of the babies will be re-evaluated 30 minutes (T1), 60 minutes (T2) and 6 hours (T3) after the bath or treatment.
|
The Newborn Comfort Behavior Scale (COMFORTneo) will assess the comfort of the newborn.
The scale will evaluate the newborn's calmness/agitation, respiratory response, pain, body movements, facial tension, and muscle tone.The scale is scored between 6-30.
As the score obtained from the scale increases, it shows that the newborn is uncomfortable and needs practices that will increase their comfort
|
The comfort level of the babies in the experimental and control groups will be evaluated 10 minutes before the treatment/bath. The comfort of the babies will be re-evaluated 30 minutes (T1), 60 minutes (T2) and 6 hours (T3) after the bath or treatment.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Perihan B Çalışkan, MSc student, Selcuk University
- Principal Investigator: Raziye Çelen, Asst. Prof., Selcuk University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023/78_TR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Phototherapy Skin Rash
-
Spectrum Pharmaceuticals, IncCompletedEGFR Inhibitor-associated RashUnited States, Canada
-
Rabin Medical CenterCompleted
-
TWi Biotechnology, Inc.CompletedEGFR Inhibitor-Induced Skin RashTaiwan
-
McGill University Health Centre/Research Institute...Terminated
-
Northwestern UniversityBayerTerminated
-
Henry Ford Health SystemWithdrawn
-
Shanghai East HospitalActive, not recruitingAcneiform EruptionsChina
-
University of Nove de JulhoUniversity of Bergen; Fundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
Sligo General HospitalEnrolling by invitationRash | Systemic Treatments | Tele-assessmentIreland
-
Azitra Inc.Prosoft ClinicalRecruitingEGFR Inhibitor-associated RashUnited States
Clinical Trials on Newborn bathing
-
Inonu UniversityCompletedNurse | Premature Newborn | Physiological MeasurementsTurkey
-
Akdeniz UniversityCompletedPremature Birth | Preterm InfantTurkey
-
China Medical University HospitalCompleted
-
Chang Gung University of Science and TechnologyRecruitingPreterm InfantsTaiwan
-
Hospital for Special Surgery, New YorkNew York Presbyterian HospitalRecruitingSurgical Wound | Post Operative Wound InfectionUnited States
-
Robert Bosch Gesellschaft für Medizinische Forschung...University Hospital Tuebingen; Wuerzburg University HospitalEnrolling by invitation
-
Akdeniz UniversityCompletedPremature | ThermoregulationTurkey
-
University of British ColumbiaCompletedStress, Psychological | Anxiety | Blood Pressure | Mental Health Wellness 1 | Environmental Exposure | Nature, HumanCanada
-
The Centre for HealthRecruiting
-
Okan UniversityCompleted